Back to top

crispr: Archive

Sundeep Ganoria

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.

REGNNegative Net Change VRTXNegative Net Change NTLAPositive Net Change CRSPNegative Net Change